EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
PDMR/Director Dealings
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that the Board of EKF has been informed that on Tuesday 9 January 2024, certain funds connected to Christopher Mills, Non-Executive Director, purchased a total of 100,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 30 pence per Ordinary Share.
Following this transaction, Christopher Mills' total direct and indirect interest in the Company is 132,250,000 Ordinary Shares, representing approximately 29.147% of the total voting rights over the Company's issued share capital.
The Notification of Dealing Form required in accordance with UK MAR is set out below as is the Standard form for notification of major holdings received by EKF today.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
|
Harwood Capital LLP and Harwood Capital Management (Gibraltar) Ltd, (the "Investment Managers") | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| Christopher Mills is the Non-Executive Director of the issuer and Chief Executive of the Investment Managers | |||
| b)
| Initial notification /Amendment
| Initial Notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| EKF Diagnostics Holdings plc | |||
| b)
| LEI
| 213800DXTF3EAUK1AR05
| |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Ordinary shares of 1 pence each | |||
| | | ||||
| Identification code | GB0031509804
| ||||
| | | ||||
| b)
| Nature of the transaction
| Purchase of Ordinary Shares | |||
| c)
| Price(s) and volume(s) | | | | |
| | | Price(s) | Volume(s) | | |
| | | 0.30 | 100,000 | | |
| | | | | | |
| d)
| Aggregated information | | |||
| | | ||||
| - Aggregated volume | N/A single transaction | ||||
| | | ||||
| - Price | | ||||
| | | ||||
| e)
| Date of the transaction
| 9 January 2024 | |||
| f)
| Place of the transaction
| London Stock Exchange, AIMX | |||
| | | | |||
| EKF Diagnostics Holdings plc | |||
| Julian Baines, Executive Chair | Tel: +44 (0)29 2071 0570 | ||
| | | ||
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 (0)20 7496 3000 | ||
| Aubrey Powell / Oliver Platts | | ||
| | | ||
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com | ||
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | ||
About EKF Life Sciences
EKF Life Sciences is a specialist global manufacturer of high-quality enzymes and custom products for use in diagnostic, pharmaceutical, and industrial applications.
EKF Life Sciences is at the forefront of supporting global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver advancements in healthcare and medicine.
Utilising its unique technical expertise, the EKF Life Sciences uses precision microbial fermentation and advanced downstream processes to isolate and deliver the highest quality enzymes and biomolecules that have been specially engineered to customer specifications.
EKF Life Sciences has two state-of-the-art GMP manufacturing facilities, located within close proximity, in Elkhart and South Bend Indiana, one the US's major life sciences and industrial hotspots. It operates to the highest regulatory standards under cGMP principles, FDA certification and ISO 13485 Quality Program. The facilities include bioreactors ranging from 5L to 14,500L, enabling it to offer an end-to-end service from bench/proof-of-concept through to full scale commercial production, providing its customers with desired yields, precision at scale and cost-efficiency.
EKF Lifesciences is also one of the market leaders for the supply of β-HB, a reagent used to detect ketones for patients suffering from diabetic ketoacidosis, as well as many other clinical applications.
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global diagnostics business focussed on:
· Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges.
· Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications, as well as other higher value Contract Manufacturing services.
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
